Addition of romiplostim to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels

Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative treatment approach for certain benign and malignant hematologic diseases. The actual HSCT is preceded by a conditioning therapy that reduces host-vs-HSCT graft rejection and creates niche space for transplanted hematopoietic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilk, C. Matthias, Kovtonyuk, Larisa V., Manz, Markus G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636308/
https://www.ncbi.nlm.nih.gov/pubmed/35736667
http://dx.doi.org/10.1182/bloodadvances.2022007566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636308/
https://www.ncbi.nlm.nih.gov/pubmed/35736667
http://dx.doi.org/10.1182/bloodadvances.2022007566

Ejemplares similares